BTK and B-cell chronic lymphocytic leukemia: BCR-induced signaling plays a key role in chronic lymphocytic leukemia (CLL), a common mature B-cell malignancy, and is an established target for therapy as illustrated by the use of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib [10].